Emory Drug Deal Turns Heads
- Cashing in on royalties. Becker, Cinda // Modern Healthcare;8/29/2005, Vol. 35 Issue 35, p18
Reports on the money received by Memorial Sloan-Kettering Cancer Center in New York from the sale of a portion of its royalty interest in cancer drugs to Royalty Pharma in 2005. Cancer drugs included in the deal; Acquisition of the U.S. royalty interest in the drugs by Royalty Pharma; Purpose...
- Gilead Drops HIV Drug Collaboration With Two Universities. Mirasol, Feliza // Chemical Market Reporter;2/9/2004, Vol. 265 Issue 6, p10
Reports on the decision of Gilead Sciences Inc. to end licensing agreement with Emory University and the University of Georgia Research Foundation Inc. in the U.S. Termination of the development of investigational drug amdoxovir; Focus on the development of investigational compounds for HIV...
- Astellas' Prosidion Subsidiary Sells Dipeptidyl Peptidase IV (DPP-IV) Patent Estate and Associated Royalty Interest to Royalty Pharma for USD 609 Mln. // Biomedical Market Newsletter;7/5/2011, p266
The article reports that the dipeptidyl peptidase IV (DDP-IV) patent estate and associated royalty interest of Prosidion Ltd. has been sold to Royalty Pharma AG for 609 million dollars in July 2011. It says that, under the agreement with the biopharmaceutical company, which is owned by Astellas...
- MSKCC plans $250 mln drug royalty sale. // Asset Securitization Report;3/7/2005, Vol. 5 Issue 9, p1
The article reports that Memorial Sloan-Kettering Cancer Center is gearing up to sell a $250 million piece of its future foreign patent royalties from cancer treatment drug Neupogen/Neulasta. Neupogen is a first-generation white blood cell booster for cancer patients receiving chemotherapy, and...
- GILEAD SCIENCES. Investor's Business Daily // Investors Business Daily;1/20/2016, pA02
The article reports on the global license and collaboration deal of Galapagos and biotechnology company Gilead Sciences Inc. for the development of drug filgotinib to treat rheumatoid arthritis and any other diseases.
- Gilead reports good HIV trial. Investor's Business Daily // Investors Business Daily;9/25/2014, pA02
The biotech reported good late-stage trial data for its new HIV drug. The trial compared a standard combination of drugs in
- COMPANY SPOTLIGHT - Gilead Sciences. // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p25
Features Gilead Sciences, a biopharmaceutical company that provides a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral, fungal and bacterial infections in the United States and Europe. Maintenance of research, development and...
- African Scientists Will Train at Emory University in Latest Drug Discovery Techniques. // Ascribe Newswire: Medicine;2/22/2007, p4
The article reports that African scientists will be trained at Emory University in Atlanta, Georgia, as part of a partnership between the university and the Republic of South Africa. The South Africa Drug Discovery Training Program will address the rising dangers of diseases that unduly affect...
- Innovation to Innovate. Boggs, Jennifer // BioWorld Today;6/13/2013, Vol. 24 Issue 113, p8
The article reports on the establishment of not-for-profit independent drug development firm Drug Innovation Venture at Emory LLC by Emory University in Atlanta, Georgia as an innovative effort to address the declining research and development activities in the biotechnology industry.